Risk Factors of Olszewski et al for 30-Day Mortality in an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL) After Rituximab-Based Immunochemotherapy
Olszewski et al identified risk factors for 30-day mortality in older adults with diffuse large B-cell lymphoma (DLBCL) after rituximab-based immunochemotherapy. These can help to identify a patient who may benefit from more aggressive management or an alternative therapeutic strategy. The authors are from Brown University, Rhode Island Hospital, Dana-Farber Cancer Institute and Harvard Medical School.
Patient selection: >= 65 years old with DLBCL, after rituximab-based immunochemotherapy
Outcome: early death (30-day mortality)
Parameters:
(1) age
(2) B symptoms
(3) ECOG performance status
(4) mobility
(5) chronic kidney disease
(6) hospitalized within past year
(7) upper endoscopy within past year
Parameter
Finding
Points
age
65 to 74.9 years
0
>= 75 years
1
B symptoms
absent
0
present
1
ECOG performance
0 to 2
0
3 or 4 (poor)
1
mobility
needs walking aid or wheelchair
1
does not need either
0
chronic kidney diseaes
absent
0
present
1
hospitalized in past year
no
0
yes
1
upper endoscopy in past year
no
0
yes
1
score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 7
• The higher the score the greater the 30-day mortality after starting therapy.
Score
30-Day Mortality
0 or 1
0.6%
2 or 3
3.2%
4 to 7
8.3%
To read more or access our algorithms and calculators, please log in or register.
